YC Application for Biotech Founders

This page covers exactly how biotech founders should approach every field of the YC application — what YC actually funds in biotech, what evidence replaces traction when you cannot launch, and how to make a biology-based company legible to generalist partners without dumbing down the science.

YC has funded biotech companies since its earliest days. The portfolio includes companies across drug discovery, diagnostics, synthetic biology, agricultural biotech, computational biology, and biotech infrastructure. YC is not looking for a traditional pharma development play — a 15-year, $2B drug development pipeline is not a YC investment. What YC funds in biotech is one of three things:

1. Biotech infrastructure and tools

Companies building the picks and shovels of the biotech industry — lab automation, DNA synthesis, cell culture platforms, bioinformatics tools, clinical trial infrastructure. These have SaaS-like revenue models and shorter timelines to commercial validation. Examples from YC's portfolio: Ginkgo Bioworks (synthetic biology platform), Zymergen (biotech R&D platform), Benchling (life sciences R&D software).

2. Diagnostics and detection

Companies building tests, sensors, or screening tools that can reach commercial validation faster than therapeutics. A diagnostic does not require Phase II and III clinical trials before it generates revenue. YC-funded diagnostics companies have reached paying hospital or clinical customers within 18-24 months of founding.

3. Biology-enabled software or tech-bio crossovers

Companies where the core product is software or a data platform but the differentiation comes from proprietary biological data or a biological workflow that competitors cannot easily replicate. These companies can demonstrate SaaS-like revenue while building a biology moat.

Traditional drug development — candidate identification, preclinical, Phase I, Phase II, Phase III, FDA approval — is generally not a YC-scale investment thesis unless the company has a platform approach that generates multiple candidates and potentially licenses or partners along the way.

What Does Your Company Do? (50 Characters)

For biotech, this field requires translating your science into a user-outcome statement. The partner reading it may not have a biology background.

Wrong (science-first):

"CRISPR-based gene editing for oncology targets"

Wrong (too vague):

"AI-powered drug discovery platform"

Right (outcome-first):

"Lab automation software for cell therapy manufacturing"

"RNA diagnostic tests for hospital-acquired infections"

"B2B platform for synthetic biology design and build"

The 50-character description should tell a non-biologist what your company does and who it does it for.

What Is Your Product?

Describe the product in plain language with one sentence of mechanism, then one sentence of the user and their workflow. Do not lead with the biology.

"Benchling-style example: we build R&D data management software for biotech labs. Researchers record experiments, track samples, and analyze results in one platform instead of across spreadsheets, paper notebooks, and disconnected instruments."

If your product is a physical or biological product (a diagnostic kit, a cell line, a reagent), describe it in terms of what it enables the user to do — not what it is made of.

What Is Your Progress?

This is where biotech founders most commonly underperform. In the absence of revenue, they either list academic publications (which partners do not weight heavily) or they say nothing meaningful (which leaves a large gap). The right approach is to state the specific scientific milestones that serve as the biotech equivalent of product traction:

Scientific validation milestones (replace revenue traction):

• Proof-of-concept data: "We have demonstrated X performance in Y conditions — here is the specific metric"
• First external validation: "We have run our test in samples from 3 external labs with Z% concordance"
• Regulatory pre-submission meeting: "We completed a pre-submission meeting with FDA in September 2024"
• First paying customer or LOI: "We have a Letter of Intent from [hospital type] for a pilot purchase of X units"
• IP position: "We have filed 2 provisional patents on the core mechanism"

The more specific and externally-validated the milestone, the stronger the signal.

Why Are You the Right Team?

Biotech team credibility requires specific credentials that partners look for:

• Scientific depth: Specific lab training, PhD program, publications in the core area (named journal and citation count matters)
• Commercial awareness: Evidence that the founding team has thought about regulatory strategy, reimbursement, and go-to-market — not just the science
• Industry bridge: At least one founder who has worked inside a biotech or pharma company, or who has relationships with potential customers and collaborators

"My cofounder completed her PhD at MIT studying RNA diagnostics and has 3 first-author publications in Nature Methods. I spent 4 years at Roche Diagnostics managing hospital accounts — I know how hospital lab directors make procurement decisions."

Pre-Data (Idea Stage)

Accepted occasionally for exceptional teams with a genuine scientific breakthrough or a clearly superior platform approach. Must have: IP filed or filing imminent, specific scientific rationale for why the approach works, and at least one team member with deep, verifiable credentials in the specific area.

Proof-of-Concept Data

The most common biotech stage at application. Must have: specific assay or platform performance data (sensitivity, specificity, yield, purity — whatever the relevant metric is), data generated in your own hands (not just published literature), and a clear statement of what additional validation is required before commercial launch.

Early Commercial / First Revenue

The strongest biotech application stage. Revenue from research reagents, software licenses, pilot sales, or contract research work demonstrates that someone has paid for something. Even $10,000 in research sales or a $50,000 pilot contract is stronger evidence than any set of scientific publications.

Regulatory Strategy Clarity

Partners specifically note whether biotech founders understand their regulatory pathway. For diagnostics: is this LDT (lab-developed test), 510(k), PMA, or De Novo? For therapeutics: what is the IND strategy and timeline? Not knowing your regulatory pathway signals commercial naivety that partners will probe.

Mistake 1: Over-explaining the science and under-explaining the business

The YC application is not a grant application or a Nature paper. Partners do not need to understand the molecular mechanism of your CRISPR system to evaluate whether your company is fundable. They need to understand: what does it do, who will pay for it, what evidence do you have that it works, and why can you build this. Lead with those questions. Science is context, not the main event.

Mistake 2: Citing academic publications as a substitute for product validation

Publications show scientific credibility. They do not show commercial viability. A first-author Nature paper demonstrates that your scientific peers found your work significant — it does not demonstrate that a hospital will pay for your diagnostic or that a pharma company will license your platform. Cite publications as one element of your team's credibility, not as the primary evidence of progress.

Mistake 3: Treating regulatory timeline as someone else's problem

Biotech founders who say "we'll figure out the regulatory path later" or "we'll hire a regulatory expert when we need one" reveal commercial naivety that partners flag immediately. Know your pathway, know the major milestones, and have at least a rough timeline estimate. It does not need to be perfect — it needs to demonstrate that you have thought seriously about it.